LDL lowering effect of PCSK9 inhibition is reduced in women
Pooled result · LDL-C reduction under PCSK9 mAb treatment (meta-analysis)Result — go to the resultMD 7.6 mg/dL 95% CI 2.7–12.4Authors' conclusion
These results demonstrate by complementary approaches that the decrease in LDL-C mediated by PCSK9 inhibition is slightly, but significantly, less marked in women than in men.
Study context
- Population
- Patients treated with PCSK9 monoclonal antibodies (mAbs) (6 real-life studies: 1216 men, 641 women); UK Biobank individuals free of lipid-lowering drugs (219,301 women, 163,512 men)UK Biobank
- Participants
- 382,813 patients
- Comparison
- Low-density lipoprotein cholesterol (LDL-C) lowering by PCSK9 inhibition in men vs women
- Outcome
- Sex-differential effect of PCSK9 inhibition on LDL-C levels
Methodological detailsUK Biobank, sex-stratified analysis
- UK Biobank
- Sex-stratified analysis
Pooled result
As reported in the abstract
LDL-C reduction under PCSK9 mAb treatment (meta-analysis)
MD
7.6 mg/dL
95% CI 2.7–12.4
P = 0.002
Menvs Women
MD 7.6 mg/dL (95% CI 2.7–12.4); P = 0.002
Further pooled results
Baseline LDL-C (meta-analysis)
MD 17.4 · P < 0.0001
Mean LDL-C difference, mg/dL
| Outcome | Men | Women |
|---|---|---|
| LDL-C difference, PCSK9-R46L homozygous carriers vs non-carriers (UK Biobank) | −35 | −26 |
- LDL-C difference, PCSK9-R46L homozygous carriers vs non-carriers (UK Biobank): P for interaction = 7.2e-04
Original publication
LDL lowering effect of PCSK9 inhibition is reduced in women. Eur Heart J Cardiovasc Pharmacother. Published 20 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →